Since CIP2A can be used as a marker for the pathogenesis of chronic myelocytic leukemia, our results showed that there was an impact of treatment on the relative expression fold for the CIP2A gene. This evidence concerns the gene CIP2A and chronic myelogenous leukemia, BCR-ABL1 positive.